2003 Biopharma Leads 
PM360
JULY 18, 2022
FINN Partners , an independent marketing and communications agency, is expanding its global footprint even further with the addition of SPAG , a leading, Asia-headquartered, health-sector communications and marketing firm with offices in Bangalore, Delhi, Indonesia, Malaysia, Mumbai, the Philippines, and Singapore. and Europe.
European Pharmaceutical Review
OCTOBER 19, 2023
billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. Can you share an update on the clinical trial for your lead candidate? Hoppin served as lead director of Noria as the two organisations were sold to Bayer Healthcare in June of 2021.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
DECEMBER 21, 2022
Production and value creation can be regionalised and decentralised, which could lead to a more resilient economic structure. During his time at Genentech Stefan has advanced several small molecules and new modalities (antibody‑drug conjugates, oligonucleotides and peptides) into the clinic as lead chemist and technical development leader.
PM360
NOVEMBER 12, 2024
One in three people is expected to develop a neurological condition in their lifetime, and neurological diseases are the leading cause of disability. From your work on the AstraMerck merger to your leadership at Alnylam, you’ve been in the biopharma industry for over 30 years. Today, the urgency has never been more apparent.
Pharmaceutical Technology
AUGUST 26, 2008
“The inherent advantages of biopharma are that it allows you to pursue therapies against targets that are not small molecule therapies, for example by targeting protein-protein interactions and targeting GPCRs (G-protein coupled receptors),” he says. “Biotechnology has exploded across the industry. .”
Silver Line CRM
SEPTEMBER 24, 2020
Yet, VMS leads the clinical educator market in patient confidence to start and maintain therapy. VMS biopharma clients expect them to move quickly — and to do so, the company saw an opportunity to streamline processes, drive efficiencies, and make it more seamless for its team to work together. .
PM360
FEBRUARY 3, 2025
It was interesting to see how the peer CEOs at the time of your published book Reinvent , not only from the biopharma sector but also fromCPG, chemicals, and many other verticals. And wrapping around these three attributes is the CEOs EQ to lead, coach, and inspirewhile having fun along the way.
Expert insights. Personalized for you.
96 
Let's personalize your content